US HB4793 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 2-0)
Status: Introduced on October 22 2019 - 25% progression, died in committee
Action: 2019-10-23 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on October 22 2019 - 25% progression, died in committee
Action: 2019-10-23 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Imposes a one cent per milligram fee on the sale of active opioids by the manufacturer, producer, or importer. The fee excludes prescription drugs used exclusively for the treatment of opioid addiction as part of a medically assisted treatment effort. The Department of Health and Human Services (HHS) must establish a program to provide rebates or discounts to cancer and hospice patients to ensure that they do not pay the fee. Any increase in federal revenues from the fee after rebates and discounts are subtracted must be distributed to states under the Substance Abuse Prevention and Treatment Block Grant program. The states must use the funds exclusively for substance abuse (including opioid abuse) efforts in the states, including (1) specified treatment programs, and (2) the recruitment and training of substance use disorder professionals to work in rural and medically underserved communities. HHS must report to Congress on the impact of this bill on the retail cost of opioids and patient access to opioid medication, the effectiveness of the discount or rebate for cancer and hospice patients, how the funds are being used to improve substance abuse treatment efforts, and suggestions for improving access to opioids for cancer and hospice patients and substance abuse treatment efforts.
Title
Budgeting for Opioid Addiction Treatment Act
Sponsors
Rep. Donald Norcross [D-NJ] | Rep. John Larson [D-CT] |
History
Date | Chamber | Action |
---|---|---|
2019-10-23 | House | Referred to the Subcommittee on Health. |
2019-10-22 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2019-10-22 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2019-10-22 | House | Introduced in House |
Same As/Similar To
SB425 (Same As) 2019-02-07 - Read twice and referred to the Committee on Finance.
Subjects
Cancer
Congressional oversight
Drug trafficking and controlled substances
Drug, alcohol, tobacco use
Health care coverage and access
Health programs administration and funding
Health promotion and preventive care
Long-term, rehabilitative, and terminal care
Prescription drugs
Sales and excise taxes
Taxation
Congressional oversight
Drug trafficking and controlled substances
Drug, alcohol, tobacco use
Health care coverage and access
Health programs administration and funding
Health promotion and preventive care
Long-term, rehabilitative, and terminal care
Prescription drugs
Sales and excise taxes
Taxation
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/4793/all-info |
Text | https://www.congress.gov/116/bills/hr4793/BILLS-116hr4793ih.pdf |